Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

Open access
Pinsky, Paul F., Prorok, Philip C., Yu, Kelly, Kramer, Barnett S., Black, Amanda, Gohagan, John K., Crawford, E. David, Grubb, Robert L., Andriole, Gerald L.·2017·Cancer

Abstract

BACKGROUND: Two large‐scale prostate cancer screening trials using prostate‐specific antigen (PSA) have given conflicting results in terms of the efficacy of such screening. One of those trials, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, previously reported outcomes with 13 years of follow‐up. This study presents updated findings from the PLCO trial. METHODS: The PLCO trial randomized subjects from 1993 to 2001 to an intervention or control arm. Intervention‐arm men received annual PSA tests for 6 years and digital rectal examinations for 4 years. This study used a linkage with the National Death Index to extend mortality follow‐up to a maximum of 19 years after randomization. RESULTS: Men were randomized to the intervention arm (n = 38,340) or the control arm (n = 38,343). The median follow‐up time was 14.8 years (25th/75th, 12.7/16.5 years) in the intervention arm and 14.7 years (25th/75th, 12.6/16.4 years) in the control arm. There were 255 deaths from prostate cancer in the intervention arm and 244 deaths from prostate cancer in the control arm; this meant a rate ratio (RR) of 1.04 (95% confidence interval [CI], 0.87‐1.24). The RR for all‐cause mortality was 0.977 (95% CI, 0.950‐1.004). It was estimated that 86% of the men in the control arm and 99% of the men in the intervention arm received any PSA testing during the trial, and the estimated yearly screening‐phase PSA testing rates were 46% and 84%, respectively. CONCLUSIONS: Extended follow‐up of the PLCO trial over a median of 15 years continues to indicate no reduction in prostate cancer mortality for the intervention arm versus the control arm. Because of the high rate of control‐arm PSA testing, this finding can be viewed as showing no benefit of organized screening versus opportunistic screening. Cancer 2017;123:592–599. © 2016 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.30474

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 256

Metadata

Authors
Pinsky, P. F., Prorok, P. C., Yu, K., Kramer, B. S., Black, A., Gohagan, J. K., Crawford, E. D., Grubb, R. L., & Andriole, G. L.
Venue
Cancer
Publisher
Wiley
Published
2016-12
Volume
123
Issue
4
Pages
592-599
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2560292269
Cited by
256
References
14
FWCI
21.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years. https://app.cochat.ai/papers/10.1002/cncr.30474
The paper
Pinsky, P. F., Prorok, P. C., Yu, K., Kramer, B. S., Black, A., Gohagan, J. K., Crawford, E. D., Grubb, R. L., & Andriole, G. L. (2017). Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years. Cancer. https://doi.org/10.1002/cncr.30474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.